(Q44729421)

5 December 2017

title

First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. (English)

1 reference

5 December 2017

1 reference

1 reference

J Johnson

1

1 reference

5 December 2017

M Pastuck

2

1 reference

5 December 2017

A Metcalfe

3

1 reference

5 December 2017

G Connors

4

1 reference

5 December 2017

R Krause

5

1 reference

5 December 2017

D Wilson

6

1 reference

5 December 2017

H Cuckle

7

1 reference

5 December 2017

publication date

6 August 2013

1 reference

5 December 2017

1 reference

5 December 2017

volume

33

1 reference

5 December 2017

issue

11

1 reference

5 December 2017

page(s)

1044-1049

1 reference

Prenatal screening for fetal aneuploidy

5 December 2017

cites work

1 reference

Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.

21 January 2018

1 reference

Antenatal screening for Down syndrome using serum placental growth factor with the combined, quadruple, serum integrated and integrated tests

21 January 2018

1 reference

Appropriate biochemical parameters in first-trimester screening for Down syndrome.

21 January 2018

1 reference

Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study

21 January 2018

1 reference

DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study

21 January 2018

1 reference

Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing

21 January 2018

1 reference

Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18.

21 January 2018

1 reference

Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18.

21 January 2018

1 reference

Clinical utility of noninvasive fetal trisomy (NIFTY) test--early experience.

21 January 2018

1 reference

Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors

21 January 2018

1 reference

Model-based screening by risk with application to Down's syndrome

21 January 2018

1 reference

Age-standardisation when target setting and auditing performance of Down syndrome screening programmes.

21 January 2018

1 reference

Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis

21 January 2018

1 reference

Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.

21 January 2018

1 reference

First-trimester screening for neural tube defects using alpha-fetoprotein

21 January 2018

1 reference

Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers

21 January 2018

1 reference

Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors

21 January 2018

1 reference

Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma

21 January 2018

1 reference

ACMG statement on noninvasive prenatal screening for fetal aneuploidy.

21 January 2018

1 reference

Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PD.4194

1 reference

5 December 2017

1 reference